Tagrisso Approved for Some With Locally Advanced, Unresectable Stage III NSCLC Following Chemoradiation

The FDA has approved osimertinib (Tagrisso, AstraZeneca) for adult patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR (epidermal growth factor receptor) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Efficacy was evaluated in LAURA (ClinicalTrials.gov. Identifier: NCT03521154), a